testes

inhibitor of aldehyde dehydrogenase 1a2 (ALDH1a2)

Deoxyribonucleic Acid Sodium (Salmon testes) is a natural DNA used in studies of DNA binding agents that modulate DNA structure and function.

Deoxyribonucleic acid, single stranded from salmon testes, is a sodium salt form of DNA derived from salmon testes. It is utilized in basal media to support the anaerobic growth of various Bacillus mojavensis strains. Additionally, it serves as a substrate for the development of DNA detection assays.

Deoxyribonucleic acid sodium salt from salmon testes (ssstDNA) is a DNA sodium salt derived from salmon testes. It is commonly used for surface modification of biomaterials to construct anti-fouling layers, passivate gold surfaces, and reduce non-specific adsorption, thereby improving the performance of sensors such as Surface plasmon resonance.

Relugolix (RVT-601) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Creatine (Methylguanidoacetic acid) is an amino acid that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine. Creatine functions as part of the cell's energy shuttle. The high energy phosphate group of ATP is transferred to creatine to form phosphocreatine in the following reaction: Cr + ATP <-> PCr + ADP. This reaction is reversibly catalyzed by creatine kinase. In the human body, creatine is synthesized mainly in the liver by the use of parts from three different amino acids: arginine, glycine, and methionine. 95% of it is later stored in the skeletal muscles and the rest is stored in the brain, heart, and testes.

5α-Androst-16-en-3α-ol is a steroid pheromone that has been found in boar testes and human male axillary sweat and has diverse biological activities.1,2It enhances GABA-activated currents in primary mouse cerebellar granule cells (EC50= 0.4 μM).25α-Androst-16-en-3α-ol (0.1-1 μM) increases the amplitude of GABA-activated currents in HEK293 cells expressing human α1β2γ2and α2β2γ2subunit-containing GABAAreceptors.In vivo, 5α-androst-16-en-3α-ol (5-10 mg/kg) decreases immobility time in the forced swim test in mice. It increases time spent in the open arms of the elevated plus maze in mice, indicating anxiolytic-like activity, when administered at doses ranging from 30 to 50 mg/kg. 5α-Androst-16-en-3α-ol protects against seizures induced by pentylenetetrazole or electroshock in mice (ED50s = 48.9 and 21.9 mg/kg, respectively). 1.Brooksbank, B.W., Brown, R., and Gustafsson, J.A.The detection of 5α-androst-16-en-3α-ol in human male axillary sweatExperientia30(8)864-865(1974) 2.Kaminski, R.M., Marini, H., Ortinski, P.I., et al.The pheromone androstenol (5α-androst-16-en-3α-ol) is a neurosteroid positive modulator of GABAA receptorsJ. Pharmacol. Exp. Ther.317(2)694-703(2006)

NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. The inhibition of NaPi2b, responsible for intestinal phosphate absorption, is considered to reduce serum phosphate levels, making it a promising therapeutic approach for hyperphosphatemia

CFG920 is a CYP17 inhibitor, is also an orally available inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential antiandrogen and antineoplastic activities. Upon oral administration, CYP17 inhibitor CFG920 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells.

Butylparaben sodium significantly impacts the later phases of spermatogenesis in the testes by impairing hormonal regulation and/or RNA and protein synthesis [1].

Kisspeptin-10, a neuropeptide present in the brains, ovaries, and testes of zebrafish, plays a critical role in gonadal development and steroid expression. At a concentration of 10 ng/ml, it enhances the mRNA levels for the luteinizing hormone (Lh) receptor and both progestin receptor a (Pra) and Prb in zebrafish ovarian follicles. In female goldfish, doses of 0.1 and 1 µg/g of Kisspeptin-10 elevate serum levels of luteinizing hormone, with no similar effect observed in male goldfish.

Relugolix-D6 is a deuterated compound of Relugolix. Relugolix (T3630) has a CAS number of 737789-87-6. Relugolix (T3630) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix (T3630) competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Relugolix (Standard) is a reference standard for research and analysis in studies involving Relugolix. Relugolix (RVT-601) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Relugolix-D6 (Standard) is a reference standard of Relugolix-D6 intended for quantitative analysis, quality control, and related biochemical research applications. Relugolix-d6 is a deuterated compound of Relugolix. Relugolix has a CAS number of 737789-87-6. Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Androstenediol 3-sulfate is a metabolite of DHEA sulfate. It serves as a crucial precursor in the synthesis of androgens within the testes and plays a significant role in the self-regulatory pathway of androgen synthesis.